Headquartered in Irving, TX Fiscal year ends December NASDAQ: CAI carislifesciences.com
Caris Life Sciences is a TechBio company that develops and commercializes precision medicine solutions, primarily in oncology. It combines comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing) with AI, machine learning and high-performance computing. Through this work it has built a large-scale, multimodal clinico-genomic database of more than 1.2 million profiles, including over 845,000 matched profiles.
The company earns most of its revenue from Molecular Profiling Services, clinical tumor and blood-based testing that ordering physicians use for therapy selection. Its products span the cancer care continuum:
- **Caris Assure**: a blood-based platform for therapy selection and, newly, therapy response monitoring.
- **Caris Confirm**: a Whole Genome, tumor-informed minimal residual disease assay targeted to launch by year-end 2026.
- **Caris Detect**: an early cancer detection offering.
- **Caris AI Insights**: AI-derived molecular signatures.
A smaller Pharma Research and Development Services segment provides data, analytics and services to biopharmaceutical companies for drug development. Caris operates in the U.S. and international markets directly or through distributor partners, with offices including Tokyo and Basel. It is listed on Nasdaq under the ticker CAI. Updated
Caris raised full-year revenue guidance to $1.04 billion to $1.05 billion after clinical case volume rose about 21% to roughly 61,500, with both lines ahead of expectations. Operating expenses jumped 42% and free cash flow swung to negative $39.7 million on an inventory build for the Caris Confirm MRD launch due before year-end.
Share prices were moving higher at midday Monday as investors were bargain hunting after Friday's dismal finish.
Caris Life Sciences is a TechBio company that develops and commercializes precision medicine solutions, primarily in oncology. It combines comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing) with AI, machine learning and high-performance computing.
The Wall Street consensus 12-month price target for CAI is $34.23.
